Compare GHI & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
| Metric | GHI | HRTX |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 203.5M |
| IPO Year | N/A | 1987 |
| Metric | GHI | HRTX |
|---|---|---|
| Price | $6.54 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $13.00 | $4.50 |
| AVG Volume (30 Days) | 154.7K | ★ 2.1M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 22.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $26,247,399.00 | ★ $155,097,000.00 |
| Revenue This Year | $201.02 | $8.98 |
| Revenue Next Year | $2.87 | $11.57 |
| P/E Ratio | $39.06 | ★ N/A |
| Revenue Growth | N/A | ★ 12.60 |
| 52 Week Low | $6.01 | $1.00 |
| 52 Week High | $13.29 | $2.68 |
| Indicator | GHI | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 69.56 |
| Support Level | $6.46 | $1.10 |
| Resistance Level | $6.73 | $1.37 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 53.50 | 91.43 |
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.